Drug news
FDA recommends approval of Perjeta for HER2+ Breast Cancer
An FDA advisory panel has voted in favor of recommending accelerated approval of Perjeta (pertuzumab), from Roche, as a neoadjuvant treatment for HER2-positive early-stage Breast Cancer. The panel said that in combination with Roche's Herceptin (trastuzumab), it had a "favourable benefit-to-risk" ratio. A decision on whether to approve Perjeta for this indication is expected by the end of October.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins